trending Market Intelligence /marketintelligence/en/news-insights/trending/8KVitaOhKgWb776UVyw30g2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cascadian Therapeutics plans common, preferred stock offerings

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Cascadian Therapeutics plans common, preferred stock offerings

Cascadian Therapeutics Inc. plans to offer and sell common stock and series E convertible preferred stock in concurrent but separate underwritten public offerings.

The company expects to grant underwriters an option to buy additional common shares.

The series E convertible preferred stocks offered are nonvoting and convertible into common shares. The conversion will be prohibited if it will result in the ownership of more than 19.99% of the company's outstanding common stock by the holder and its affiliates.

Net proceeds of the offerings will be used to fund the tucatinib HER2CLIMB trial, to support its development in other indications through company- or investigator-sponsored trials, as well as for working capital and other general corporate purposes.

Cowen and Co. LLC and Barclays Capital Inc. are acting as joint book-running managers. Raymond James & Associates Inc. is acting as the lead manager, with BTIG LLC acting as a co-manager in the offerings.